Green zone Gastroenteroloji

Bile Acid-Associated Diarrhea

Bile acid-associated diarrhea occurs when bile acids that cannot be reabsorbed in the terminal ileum pass into the colon and increase water and salt secretion. Its CLINICAL SIGNIFICANCE comes from the fact that, despite being FREQUENT, it is almost never considered and its treatment is EFFECTIVE.

The MOST FREQUENTLY OVERLOOKED GROUP is patients followed with a diagnosis of diarrhea-predominant irritable bowel syndrome; in a significant portion of patients followed with this diagnosis, this condition is present and they improve noticeably with appropriate treatment. There are THREE MAIN GROUPS: (1) TERMINAL ILEUM DISEASE or RESECTION (Crohn’s disease, surgery); (2) POST-CHOLECYSTECTOMY; (3) WITHOUT A CLEAR CAUSE, due to a disorder in the regulation of bile acid production.

TYPICAL PATTERN: WATERY diarrhea, URGENCY FOR DEFECATION, often in the MORNING and AFTER MEALS, sometimes at NIGHT.

Since specific diagnostic tests are not available everywhere, a THERAPEUTIC TRIAL in the appropriate patient can be used diagnostically. TREATMENT involves the use of BILE ACID BINDERS; however, BINDERS INTERFERE WITH THE ABSORPTION OF OTHER MEDICATIONS and timing should be planned separately.

Rapid management

MECHANISM: bile acids are normally reabsorbed in the TERMINAL ILEUM; when they are not absorbed, they pass into the COLON and cause diarrhea by INCREASING water and salt secretion.
CLINICAL SIGNIFICANCE:
FREQUENTLY seen, ALMOST NEVER considered, and TREATABLE effectively.
MOST COMMONLY OVERLOOKED GROUP: patients followed with the diagnosis of DIARRHEA-PREDOMINANT IRRITABLE BOWEL SYNDROME — in a SIGNIFICANT PORTION of those followed with this diagnosis the underlying issue is present and responds CLEARLY to appropriate treatment (related protocol).
THREE MAIN GROUPS: (1) TERMINAL ILEUM DISEASE or RESECTION — Crohn's disease, ileum surgery, radiation damage (here the mechanism is CLEAR and should be expected); (2) AFTER CHOLECYSTECTOMY — bile flow becomes continuous; this should be considered in PROLONGED post-surgical diarrhea; (3) WITHOUT CLEAR CAUSE — a defect in the feedback regulation of bile acid production; this group is most often overlooked.
TYPICAL PATTERN:
WATERY diarrhea | URGENCY | often in the MORNING and AFTER MEALS | sometimes AT NIGHT (this may help distinguish from functional disorders).
DIAGNOSIS: specific tests are NOT AVAILABLE EVERYWHERE → a TREATMENT TRIAL can be used diagnostically in an appropriate patient; response is usually RAPID.
TREATMENT:
BILE ACID BINDERS | CRITICAL WARNING:
BINDERS IMPAIR ABSORPTION OF OTHER MEDICATIONS — timing must be planned SEPARATELY.
Monitor for FAT-SOLUBLE VITAMIN deficiency.

Drug	Adult	Pediatric	Route	Duration
Raising suspicion of the diagnosis and recognizing risk groups The most distinctive feature of bile acid-related diarrhea is the gap between its frequency and rate of recognition. Although it is a common cause of chronic diarrhea, it remains in the background on routine differential diagnosis lists and is therefore not investigated. Three groups should be considered separately. In patients with terminal ileum disease or resection, the mechanism is clear; this area is the only place where bile acids are reabsorbed, and when damaged, diarrhea is an expected outcome, so the diagnosis should be considered in these patients. In patients who have had a cholecystectomy, bile flow becomes continuous, which in some patients leads to diarrhea; this possibility should be evaluated in post-operative persistent diarrhea. The third group consists of patients without a clear cause; here, the problem lies in the feedback regulation of bile acid production, and this group is most often overlooked.	THREE GROUPS should be questioned: TERMINAL ILEUM disease or RESECTION (Crohn's disease, surgery, radiation), history of CHOLECYSTECTOMY, and cases developing without a clear cause. This diagnosis should be considered in chronic watery diarrhea.	It should be considered in children with ileum resection or disease	—	During the evaluation process
Re-evaluation of the irritable bowel syndrome diagnosis The diagnosis of diarrhea-predominant irritable bowel syndrome is often made in patients with chronic diarrhea whose tests are normal; this diagnosis is correct in most patients, but in a portion, there is an underlying unrecognized bile acid-related diarrhea. The symptoms of the two conditions largely overlap: both involve watery diarrhea, urgency to defecate, and abdominal discomfort, and routine tests come back normal. The importance of differentiation comes from the fact that treatment is completely different. Treatments aimed at irritable bowel syndrome do not provide sufficient response in these patients, while response to bile acid binders is usually rapid and clear. Therefore, in patients monitored with a functional diagnosis who do not respond to treatment, this possibility should be re-evaluated; suspicion should especially increase in diarrhea that intensifies in the morning and after meals, includes urgency, and sometimes occurs at night.	In a significant portion of patients followed with the diagnosis of DIARRHEA-PREDOMINANT IRRITABLE BOWEL SYNDROME, this condition underlies it; especially in patients who do not respond to treatment, the diagnosis should be re-evaluated (relevant protocol)	Functional bowel diseases in children are evaluated separately	—	During the evaluation process
Evaluation of the clinical pattern In this table, the timing of diarrhea provides a diagnostic clue and should also be asked when taking a history. Since bile acids are released into the intestine with meals, diarrhea typically occurs after meals and is especially prominent in the mornings; the patient describes the urgent need to rush to the toilet immediately after breakfast. The urgency of defecation is significant and limits the patient's daily life; some patients do not leave the house due to anxiety about not reaching the toilet in time. Nighttime defecation may also occur, and this finding can be distinctive; in functional bowel diseases, complaints usually do not disturb sleep, so nocturnal diarrhea suggests an organic cause. This pattern alone does not establish a diagnosis but significantly increases suspicion and requires reevaluation of the diagnosis, particularly in patients followed with a diagnosis of irritable bowel syndrome.	TYPICAL PATTERN: WATERY diarrhea, marked URGENCY TO DEFECATE, often intensifying in the MORNING and after MEALS, sometimes NIGHT defecation. Night-time defecation can be distinguishing from functional diseases and should be questioned	Pattern assessment in children is done together with the family	—	During the evaluation process
Diagnostic use of a treatment trial Specific tests used in the diagnosis of bile acid-related diarrhea are not accessible in many centers; this is one of the practical barriers to establishing the diagnosis. Therefore, in appropriately selected patients, a treatment trial with a bile acid binder can be used as both a diagnostic and therapeutic step. The advantage of this approach is that the response is usually rapid and significant; a patient who has lived with diarrhea for years can experience noticeable relief within days. However, two conditions must be met before the trial. The first is the evaluation of alarm signs; if bleeding, weight loss, or anemia is present, the cause of these findings should be investigated first. The second is the exclusion of other chronic diarrhea causes; diagnoses such as celiac disease, microscopic colitis, and inflammatory bowel disease should be reviewed. When these conditions are met, the trial is a safe and effective approach.	Since SPECIFIC tests are NOT AVAILABLE EVERYWHERE, a TREATMENT TRIAL with a BILE ACID BINDER can be used diagnostically in appropriate patients; the response is usually RAPID. Alarm findings should be evaluated before the trial, and other causes should be excluded.	In children, the decision for a treatment trial is made with a pediatric specialist.	PO	Specified duration
Effects of binders on drug absorption Bile acid binders act by binding bile acids in the intestinal lumen; however, this binding is not selective and also affects other substances present in the same environment. The practical result of this is reduced absorption of concomitantly taken drugs, which is an interaction that is often overlooked. This effect is particularly important in drugs with a narrow therapeutic range; in a patient taking thyroid hormone, reduced absorption can lead to disruption in thyroid function tests, and in a patient on anticoagulants, it can cause fluctuations in coagulation values. Since these interactions occur even when drug doses are not changed, they may seem inexplicable if it is not known that binding therapy has been started. Therefore, the current drug list should be reviewed and intake times should be scheduled separately for every patient starting binder therapy; this rule should be clearly explained to the patient.	BILE ACID BINDERS IMPAIR THE ABSORPTION OF OTHER DRUGS; the timing of taking other drugs should be planned SEPARATELY. Special attention is required for THYROID HORMONE, ANTICOAGULANTS, DIGITALIS, and fat-soluble vitamins. Timing intervals MUST BE VERIFIED FROM THE INSTITUTIONAL PROTOCOL.	In children, dose and timing are determined according to the pediatric protocol.	PO	During treatment
Long-term monitoring and vitamin status The nutritional effects of long-term use of bile acid binders are often not monitored. Bile acids are necessary for the digestion of fats and the absorption of fat-soluble vitamins; since binders bind these acids, high-dose and long-term use may reduce the absorption of these vitamins. This effect usually develops insidiously and progresses without symptoms; therefore, vitamin status should be evaluated in patients receiving long-term treatment. A second and separate issue is related to the underlying cause. In patients with terminal ileum disease or resection, not only bile acids but also vitamin B12 cannot be absorbed; these two absorptions occur in the same region. Therefore, B12 deficiency is an expected problem in this patient group and should also be investigated; the deficiency develops silently and its neurological effects can be irreversible.	In long-term use of binders, FAT-SOLUBLE VITAMIN (A, D, E, K) status should be monitored. In patients with terminal ileum disease or resection, B12 DEFICIENCY should also be investigated (relevant protocol).	In children, growth and vitamin status should be regularly monitored.	—	The reason why long-term

Alternative

In patients with terminal ileum disease, the treatment of the underlying disease takes priority (relevant protocol).
In patients unresponsive to binding therapy, the diagnosis should be reevaluated and other causes of chronic diarrhea should be investigated.
Alternative options should be considered for patients who cannot tolerate the drug form or method of intake.
In diarrhea persisting after cholecystectomy, this diagnosis should be considered, but other causes should also be reviewed.
Celiac disease, microscopic colitis, and bacterial overgrowth in the small intestine may coexist (relevant protocols).
In patients followed with a diagnosis of irritable bowel syndrome and unresponsive to treatment, this possibility should be primarily evaluated (relevant protocol).
In patients with extensive terminal ileum resection, binding therapy may worsen fat malabsorption, and the approach is different.

Red flags

In chronic watery diarrhea, NOT CONSIDERING this diagnosis → it is common, treatment is EFFECTIVE, and if not recognized, the patient lives with complaints for years.
NOT QUESTIONING THE DIAGNOSIS OF DIARRHEA-PREDOMINANT IRRITABLE BOWEL SYNDROME → in a significant portion of those followed with this diagnosis, this underlying condition exists.
IGNORING NIGHTTIME STOOLING → in functional diseases, complaints usually do not INTERRUPT sleep; nighttime diarrhea suggests an organic cause.
Not considering this possibility in diarrhea persisting after CHOLECYSTECTOMY.
Not expecting diarrhea in a patient with TERMINAL ILEUM disease or resection → this region is the ONLY place where bile acids are absorbed.
Not knowing that BINDERS may impair the absorption of other drugs → can have serious consequences in THYROID HORMONE, ANTICOAGULANT, and DIGITALIS; timing should be planned SEPARATELY.
Not monitoring FAT-SOLUBLE VITAMINS during long-term use → the effect develops INSIDIOUSLY.
Not investigating B12 DEFICIENCY in a patient with terminal ileum involvement → it is absorbed in the same region, and neurological damage may be IRREVERSIBLE.
Starting treatment in the presence of ALARM FINDINGS (bleeding, weight loss, anemia) → the cause of these findings should be investigated first.
Not reevaluating the diagnosis in unresponsiveness to treatment → other causes of chronic diarrhea should be investigated.

Disposition and follow-up

Green zone: Chronic watery diarrhea without alarm signs: outpatient evaluation, exclusion of other causes, and a trial of treatment in suitable patients.
Yellow zone: Alarm signs, treatment unresponsiveness, significant weight loss, or suspicion of underlying disease: advanced evaluation and specialist referral.
Red zone: Severe dehydration, electrolyte disturbance, gastrointestinal bleeding, or systemic symptoms: urgent evaluation (relevant protocols).

Key clinical points

READ FIRST — common, almost never considered

MECHANISM: bile acids are normally reabsorbed in the TERMINAL ILEUM; if not absorbed, they pass into the COLON and increase water and salt secretion → diarrhea | CLINICAL SIGNIFICANCE: despite being a common cause of chronic diarrhea, it remains in the BACKGROUND of routine differential diagnosis lists → often not investigated; however, TREATMENT IS EFFECTIVE | THREE MAIN GROUPS: (1) TERMINAL ILEUM DISEASE or RESECTION (CROHN’S, surgery, radiation) — mechanism is CLEAR, this is the ONLY place where bile acids are absorbed, diarrhea is an EXPECTED outcome; (2) POST-CHOLECYSTECTOMY — bile flow becomes CONTINUOUS; should be considered in post-surgical PROLONGED diarrhea; (3) WITHOUT OBVIOUS CAUSE — a defect in the FEEDBACK regulation of bile acid production; THIS GROUP IS MOST FREQUENTLY OVERLOOKED

The most notable feature of bile acid–related diarrhea is the gap between its frequency and recognition rate. Although it is one of the common causes of chronic diarrhea, it remains in the background of routine differential diagnosis lists and therefore is not investigated. The three groups should be considered separately. In patients with terminal ileum disease or resection, the mechanism is clear; this region is the only place where bile acids are reabsorbed, and diarrhea is an expected result if it is damaged. In patients who have undergone cholecystectomy, bile flow becomes continuous and this can lead to diarrhea in some patients; this possibility should be evaluated in prolonged post-surgical diarrhea. The third group comprises patients without an obvious cause; here the problem lies in the feedback regulation of bile acid production, and this group is most often overlooked.

THE MOST FREQUENTLY OVERLOOKED GROUP — 'diarrhea-predominant irritable bowel syndrome'

This diagnosis is frequently made in patients with chronic diarrhea and NORMAL TEST RESULTS — it is correct in most patients, but in a portion of them, there is an underlying UNRECOGNIZED bile acid–related diarrhea | SYMPTOMS LARGELY OVERLAP: in both, there is WATERY diarrhea, URGENCY TO DEFECATE, and abdominal discomfort, with routine tests coming back NORMAL | IMPORTANCE OF DISTINCTION: TREATMENT IS ENTIRELY DIFFERENT — treatments aimed at irritable bowel syndrome do NOT PROVIDE SATISFACTORY RESPONSE in these patients, whereas RESPONSE TO BILE ACID BINDERS is generally RAPID and CLEAR | RULE: in patients monitored with a functional diagnosis and NOT RESPONDING TO TREATMENT, this possibility SHOULD BE RE-EVALUATED (relevant protocol) | PATTERN THAT INCREASES SUSPICION: diarrhea that intensifies in the MORNING and AFTER MEALS, with URGENCY and sometimes at NIGHT

A diagnosis of diarrhea-dominant irritable bowel syndrome is frequently made in patients with chronic diarrhea and normal test results; this diagnosis is correct in most patients, but in a portion of them, there is underlying unrecognized bile acid–related diarrhea. The symptoms of the two conditions largely overlap: both have watery diarrhea, urgency to defecate, and abdominal discomfort, with routine tests being normal. The importance of distinguishing them comes from the fact that treatment is entirely different. Treatments for irritable bowel syndrome do not provide sufficient response in these patients, while response to bile acid binders is generally rapid and clear. Therefore, in patients monitored with a functional diagnosis and not responding to treatment, this possibility should be re-evaluated.

TIMING provides a diagnostic clue — ask about the night

Since bile acids are released into the intestine with MEALS, diarrhea typically intensifies POST-PRANDIALLY, especially in the MORNINGS → the patient describes an immediate need to rush to the bathroom AFTER BREAKFAST | DEFECATION URGENCY is prominent and RESTRICTS daily life: some patients do not leave home out of FEAR OF NOT REACHING THE TOILET | NIGHT-TIME DEFECATION may also occur and THIS FINDING CAN BE DISTINCTIVE: symptoms in functional bowel diseases generally do NOT INTERRUPT SLEEP → NIGHT DIARRHEA suggests an ORGANIC cause | This pattern alone does not establish the diagnosis, but it STRONGLY INCREASES SUSPICION and especially requires RE-EVALUATION of the diagnosis in patients monitored with an irritable bowel syndrome diagnosis

In this table, the timing of diarrhea provides a diagnostic clue and should also be questioned when taking the history. Since bile acids empty into the intestine along with meals, the diarrhea typically occurs in postprandial periods and is especially pronounced in the mornings; the patient describes an immediate need to rush to the toilet after breakfast. The urgency of defecation is significant and restricts the patient's daily life; some patients do not leave the house due to fear of not reaching the toilet in time. Nighttime defecation may also be observed, and this finding can be distinctive; in functional bowel diseases, complaints usually do not interrupt sleep, so nocturnal diarrhea suggests an organic cause. This pattern alone does not make a diagnosis but markedly increases suspicion.

A TREATMENT TRIAL can be used diagnostically

Specific tests are NOT AVAILABLE at MANY CENTERS — this is one of the PRACTICAL BARRIERS to making the diagnosis | THEREFORE: in appropriately selected patients, a TRIAL OF TREATMENT with a BILE ACID BINDER can be used as both a DIAGNOSTIC and THERAPEUTIC step | ADVANTAGE: the response is usually RAPID and NOTICEABLE — a patient who has been living with diarrhea for YEARS can significantly improve in DAYS | TWO CONDITIONS BEFORE THE TRIAL: (1) EVALUATION OF ALARM SIGNS — in the presence of BLEEDING, WEIGHT LOSS, or ANEMIA, the cause of these findings should be investigated FIRST; (2) EXCLUSION OF OTHER CHRONIC DIARRHEA CAUSES — celiac disease, microscopic colitis, and inflammatory bowel disease should be reviewed (relevant protocols) | When these conditions are met, the trial is a SAFE and EFFECTIVE approach | If there is no response, the diagnosis should be REEVALUATED

Specific tests used to diagnose bile acid–related diarrhea are not available at many centers; this is one of the practical barriers to making the diagnosis. Therefore, in appropriately selected patients, a trial of treatment with a bile acid binder can be used as both a diagnostic and therapeutic step. The advantage of this approach is that the response is usually rapid and noticeable; a patient who has been living with diarrhea for years can show significant improvement within days. However, two conditions must be met before the trial. The first is the evaluation of alarm signs; in the presence of bleeding, weight loss, or anemia, the cause of these findings should be investigated first. The second is the exclusion of other chronic diarrhea causes.

BINDERS interfere with the absorption of other drugs

Binders bind bile acids in the intestinal lumen — HOWEVER, THIS BINDING IS NOT SELECTIVE and also affects OTHER SUBSTANCES in the same environment | PRACTICAL CONSEQUENCE: the ABSORPTION OF MEDICATIONS taken together is reduced — this is an interaction that is FREQUENTLY OVERLOOKED | IT IS PARTICULARLY IMPORTANT for drugs with a NARROW THERAPEUTIC RANGE: decreased absorption in a patient taking THYROID HORMONE can lead to abnormalities in THYROID FUNCTION TESTS | in a patient using ANTICOAGULANTS, it can cause fluctuations in COAGULATION VALUES | in a patient taking DIGITALIS, it can lead to level changes | DANGER: since these interactions occur without changing the DRUG DOSES, they appear inexplicable if it is UNKNOWN that binder therapy has started | RULE: in every patient starting binders, the EXISTING DRUG LIST should be reviewed and INTAKE TIMES scheduled separately; this rule should be EXPLAINED CLEARLY to the patient | Timing intervals should be VERIFIED FROM THE INSTITUTIONAL PROTOCOL

Bile acid binders exert their effect by binding bile acids in the intestinal lumen; however, this binding is not selective and also affects other substances present in the same environment. The practical consequence is reduced absorption of concomitantly taken drugs, and this is an interaction that is frequently overlooked. The effect is particularly important for drugs with a narrow therapeutic range; reduced absorption in a patient taking thyroid hormone can lead to abnormalities in thyroid function tests, and in a patient using anticoagulants, it can cause fluctuations in coagulation values. Since these interactions occur without changing the drug doses, they appear inexplicable if it is unknown that binder therapy has started. Therefore, in every patient starting binders, the drug list should be reviewed and intake times should be scheduled separately.

Detailed assessment

Diagnostic and decision reasoning

Clinical framework

Overview

Bile acid-related diarrhea occurs when bile acids that cannot be reabsorbed in the terminal ileum pass into the colon, increasing water and salt secretion. Its clinical significance arises from the fact that despite being common, it is almost never considered, and its treatment is effective.

There are three main groups. The first includes patients with terminal ileum disease or resection; since this is the only place where bile acids are reabsorbed, the mechanism is clear here and diarrhea is an expected outcome.

The second group consists of patients who have undergone cholecystectomy; continuous bile flow can cause diarrhea in some patients. The third group includes patients in whom no obvious cause is found and who develop the condition due to a disorder in the regulation of bile acid production; this group is the most frequently overlooked.

The most commonly missed patient population are those monitored with a diagnosis of diarrhea-predominant irritable bowel syndrome; in a significant portion of these patients, this underlying condition exists and they improve markedly with appropriate treatment. The typical pattern is watery diarrhea, marked urgency in defecation, intensification in the morning and after meals, and sometimes nighttime defecation.

Since specific tests are not available everywhere, a trial of treatment can be used diagnostically in suitable patients. Binders interfere with the absorption of other drugs, so timing should be planned separately.

Differential diagnosis and assessment

Key considerations

Diarrhea-predominant irritable bowel syndrome is the most frequently confused diagnosis, and in some of these patients, this underlying condition is present (see related protocol).
Celiac disease is a common cause of chronic diarrhea and should be excluded (see related protocol).
Microscopic colitis is recognized by biopsy even if colonoscopy appears normal (see related protocol).
Bacterial overgrowth in the small intestine causes similar complaints and can be present simultaneously (see related protocol).
Inflammatory bowel disease, particularly with terminal ileum involvement, is both a cause and a differential diagnosis (see related protocol).
Carbohydrate malabsorption mainly causes complaints of gas and bloating (see related protocol).
Exocrine pancreatic insufficiency is distinguished by fat malabsorption (see related protocol).
Colorectal cancer and other organic causes should be excluded if alarm findings are present (see related protocol).

Clinical decision reasoning

Why it matters

The points that determine the clinical outcome in the management of bile acid-related diarrhea result from the failure to consider the diagnosis and the effectiveness of its treatment. The first point is awareness; although this condition is a common cause of chronic diarrhea, it remains secondary in the differential diagnosis lists and is not investigated.

Considering the three groups separately ensures this awareness; diarrhea should be expected in patients with terminal ileum involvement, this possibility should be assessed in diarrhea persisting after cholecystectomy, and the group without a clear cause should be kept in mind. The second and most practically valuable point is the reassessment of patients monitored with a predominant diagnosis of irritable bowel syndrome.

The symptoms of the two conditions overlap, and routine tests are normal in both; however, their treatments are completely different, and the response to binders is rapid and marked. The third point is the diagnostic value of timing; the concentration of diarrhea in the morning and after meals is consistent with the mechanism, while nocturnal bowel movements may help distinguish it from functional diseases.

The fourth point is the diagnostic use of a treatment trial; since access to specific tests is limited, this approach is practical, but alarm symptoms should be evaluated and other causes excluded. The fifth point is that binders interfere with drug absorption; since this interaction occurs even without dose changes, it may seem inexplicable and can lead to serious consequences, especially with drugs that have a narrow therapeutic range.

Finally, in long-term use, vitamin status should be monitored, and in patients with terminal ileum involvement, B12 deficiency should be observed.

Safety and monitoring

Complications and safety

Critical complications

Significant impairment in quality of life and social restriction are common due to the urgency of bowel movements.
Fluid and electrolyte loss can develop in severe cases.
Fat-soluble vitamin deficiencies may arise during long-term binder use.
B12 deficiency develops in patients with terminal ileum involvement, and neurological damage can be irreversible.
Decreased absorption of other drugs can have serious consequences in thyroid and anticoagulant treatments.
Symptoms lasting for years and unnecessary tests occur due to delayed diagnosis.
Constipation can develop when the binder dose is high.
In patients with extensive ileum resection, binder therapy can worsen fat malabsorption.

Special patient populations

Special considerations

This scenario should be expected in patients with terminal ileum resection or Crohn's disease (relevant protocol).
This possibility should be evaluated in patients who have undergone cholecystectomy and continue to have postoperative diarrhea.
In patients followed with the diagnosis of diarrhea-dominant irritable bowel syndrome and who are unresponsive, the diagnosis should be reconsidered (relevant protocol).
The timing of intake should be specially planned in patients using thyroid hormone, anticoagulants, or digitalis.
In patients with extensive ileum resection, the binding therapy approach is different and requires expert decision.
In patients with radiation enteritis, this mechanism contributes to the scenario (relevant protocol).
Vitamin status should be regularly monitored in patients receiving long-term therapy.
Evaluation in children with ileum disease or resection should be done with a pediatric specialist.

Follow-up and reassessment

Follow-up plan

During follow-up, treatment response, drug interactions, and nutritional status should be evaluated together. In patients undergoing a treatment trial, the response should be evaluated within the determined period; in patients who do not respond, the diagnosis should be re-examined and other causes of chronic diarrhea should be investigated.

In patients using binders, the medication list should be reviewed at each visit, and it should be confirmed that the intake times of newly started medications are separately planned; especially in patients using thyroid hormone, anticoagulants, and digitalis, relevant laboratory values should be monitored, because absorption changes can lead to deterioration even if the dose is not changed. Fat-soluble vitamin status should be evaluated in patients receiving long-term therapy.

In patients with terminal ileum disease or resection, B12 levels should be monitored and replacement should be planned if a deficiency is detected; this deficiency develops insidiously and its neurological effects can be irreversible. In patients with underlying disease, the treatment of that disease should be continued and its activity monitored.

The dose should be reviewed in patients who develop constipation. Newly emerging bleeding, weight loss, or anemia should be investigated without attributing them to the natural course of the disease.

Quality of life and social limitations should be questioned.